Funder
National Cancer Institute
Geoffrey Beene Cancer Research Center at Memorial Sloan Kettering Cancer Center
Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. Griggs JJ, Sorbero ME, Lyman GH (2005) Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 165:1267–1273
2. Lyman GH, Dale DC, Crawford J (2003) Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncology: Official J Am Soc Clin Oncol 21:4524–4531
3. Madarnas Y, Sawka CA, Franssen E, Bjarnason GA (2001) Are medical oncologists biased in their treatment of the large woman with breast cancer? Breast Cancer Res Treat 66:123–133
4. Carroll JP, Protani MM, Nguyen L, Cheng ME, Fay M, Saleem M, Pillay PS, Walpole E, Martin JH (2014) Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women. Med Oncol 31:881
5. Gouerant S, Leheurteur M, Chaker M, Modzelewski R, Rigal O, Veyret C, Lauridant G, Clatot F (2013) A higher body mass index and fat mass are factors predictive of docetaxel dose intensity. Anticancer Res 33:5655–5662